Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0031 in Advanced RET-altered NSCLC
NCT05443126Phase 2Recruiting
- Sponsor
- Ellipses Pharma
- Start
- Sep 2022
- Primary completion
- Mar 2027
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of a400 in non-small cell lung cancer (NSCLC), sponsored by Ellipses Pharma. Started Sep 2022; status: recruiting.
02
Drugs
a400
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05443126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443126.